STOCK TITAN

Baird Medical and ExcelFin Acquisition Corp Complete Business Combination

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)

Baird Medical, a leading microwave ablation (MWA) medical device developer in China with recent expansion into the U.S. market, and ExcelFin Acquisition Corp (NASDAQ: XFIN) have completed their business combination. The resulting company, Baird Medical Investment Holdings (PubCo), will begin trading on Nasdaq under the symbols 'BDMD' and 'BDMDW' on October 2, 2024.

At ExcelFin's special meeting, 99.9% of votes cast approved the business combination. Upon completion, founders of Baird Medical and Grand Fortune Capital, subscribed to a $4,900,000 Convertible Preferred investment in the Company. The transaction involved various advisors, including Dechert LLP, Allen Overy Shearman Sterling US LLP, and Cohen & Company Capital Markets, among others.

Baird Medical, uno dei principali sviluppatori di dispositivi medici per ablazione a microonde (MWA) in Cina con recente espansione nel mercato statunitense, e ExcelFin Acquisition Corp (NASDAQ: XFIN) hanno completato la loro fusione aziendale. La società risultante, Baird Medical Investment Holdings (PubCo), inizierà a essere quotata su Nasdaq con i simboli 'BDMD' e 'BDMDW' il 2 ottobre 2024.

Durante l'assemblea speciale di ExcelFin, il 99,9% dei voti espressi ha approvato la fusione aziendale. Al termine dell'operazione, i fondatori di Baird Medical e Grand Fortune Capital hanno sottoscritto un investimento convertibile preferenziale di 4.900.000 dollari nella Società. La transazione ha coinvolto diversi consulenti, tra cui Dechert LLP, Allen Overy Shearman Sterling US LLP e Cohen & Company Capital Markets, tra gli altri.

Baird Medical, un desarrollador líder de dispositivos médicos de ablación por microondas (MWA) en China con una reciente expansión en el mercado estadounidense, y ExcelFin Acquisition Corp (NASDAQ: XFIN) han completado su fusión empresarial. La empresa resultante, Baird Medical Investment Holdings (PubCo), comenzará a cotizar en Nasdaq bajo los símbolos 'BDMD' y 'BDMDW' el 2 de octubre de 2024.

En la reunión especial de ExcelFin, el 99,9% de los votos emitidos aprobó la fusión empresarial. Al finalizar, los fundadores de Baird Medical y Grand Fortune Capital suscribieron un inversión preferente convertible de 4.900.000 dólares en la Compañía. La transacción involucró a varios asesores, incluyendo a Dechert LLP, Allen Overy Shearman Sterling US LLP y Cohen & Company Capital Markets, entre otros.

바이어드 메디컬(Baird Medical)은 중국의 선도적인 마이크로웨이브 절제(MWA) 의료기기 개발업체로 최근 미국 시장으로 확장하였으며, ExcelFin 인수 주식회사(NASDAQ: XFIN)와 함께 사업 결합을 완료하였습니다. 결과적인 회사인 Baird Medical Investment Holdings (PubCo)는 2024년 10월 2일에 'BDMD'와 'BDMDW' 기호로 나스닥에서 거래를 시작할 예정입니다.

ExcelFin의 특별 회의에서 99.9%의 투표가 사업 결합을 승인했습니다. 완료 후, 바이어드 메디컬과 그랜드 포춘 캐피탈의 창립자는 회사에 4,900,000달러의 전환 우선주 투자를 구독했습니다. 이 거래에는 Dechert LLP, Allen Overy Shearman Sterling US LLP 및 Cohen & Company Capital Markets를 포함한 다양한 자문들이 참여했습니다.

Baird Medical, un développeur de dispositifs médicaux de pointe en ablation par micro-ondes (MWA) en Chine avec une récente expansion sur le marché américain, et ExcelFin Acquisition Corp (NASDAQ: XFIN) ont achevé leur combinaison d'affaires. La société résultante, Baird Medical Investment Holdings (PubCo), commencera à être cotée sur le Nasdaq sous les symboles 'BDMD' et 'BDMDW' le 2 octobre 2024.

Lors de la réunion spéciale d'ExcelFin, 99,9 % des votes exprimés ont approuvé la combinaison d'affaires. À l'issue de la transaction, les fondateurs de Baird Medical et Grand Fortune Capital ont souscrit à un investissement convertible préférentiel de 4 900 000 dollars dans la Société. La transaction a impliqué divers conseillers, dont Dechert LLP, Allen Overy Shearman Sterling US LLP et Cohen & Company Capital Markets, parmi d'autres.

Baird Medical, ein führender Entwickler von Mikrowellenablation (MWA) Medizinprodukten in China mit jüngster Expansion auf den US-Markt, und ExcelFin Acquisition Corp (NASDAQ: XFIN) haben ihre Unternehmensfusion abgeschlossen. Das resultierende Unternehmen, Baird Medical Investment Holdings (PubCo), wird am 2. Oktober 2024 unter den Symbolen 'BDMD' und 'BDMDW' an der Nasdaq gehandelt.

Auf der außerordentlichen Sitzung von ExcelFin haben 99,9 % der abgegebenen Stimmen die Unternehmensfusion genehmigt. Nach Abschluss der Transaktion haben die Gründer von Baird Medical und Grand Fortune Capital in eine 4.900.000-Dollar konvertible Vorzugsinvestition in das Unternehmen investiert. Die Transaktion umfasste verschiedene Berater, darunter Dechert LLP, Allen Overy Shearman Sterling US LLP und Cohen & Company Capital Markets, unter anderem.

Positive
  • Successful completion of the business combination between Baird Medical and ExcelFin
  • New company (PubCo) to be listed on Nasdaq, potentially increasing visibility and liquidity
  • Strong shareholder approval with 99.9% of votes in favor of the business combination
  • $4,900,000 Convertible Preferred investment from founders and co-sponsor
Negative
  • None.

Insights

The completion of the business combination between Baird Medical and ExcelFin Acquisition Corp marks a significant milestone for both companies. This deal creates a new publicly traded entity, Baird Medical Investment Holdings (PubCo), which will trade on Nasdaq under the ticker "BDMD".

Key points to consider:

  • High shareholder approval: 99.9% of votes cast were in favor of the business combination, indicating strong investor confidence.
  • Additional capital injection: Founders and co-sponsors invested $4,900,000 in Convertible Preferred shares, strengthening the company's financial position.
  • Market expansion potential: Baird Medical's recent FDA clearances for its microwave ablation devices open up opportunities in the lucrative U.S. market.
  • Liquidity for investors: The public listing provides liquidity for early investors and access to capital markets for future growth.

While this transaction appears positive for stakeholders, investors should monitor the company's ability to execute its U.S. market entry strategy and financial performance post-merger.

The merger between Baird Medical and ExcelFin is noteworthy for the medical device industry, particularly in the microwave ablation (MWA) sector. Baird Medical's leading position in China's MWA market, coupled with recent FDA 510(k) clearances, positions the company for potential growth in the U.S.

Key considerations for investors:

  • Market opportunity: The global MWA market is expanding, driven by increasing cancer prevalence and demand for minimally invasive procedures.
  • Regulatory progress: FDA clearances suggest the company's technology meets U.S. safety and efficacy standards, a important step for market entry.
  • Competitive landscape: While Baird Medical is established in China, it will face stiff competition from incumbent MWA providers in the U.S.
  • R&D capabilities: The merger may provide additional resources for product development and clinical trials, potentially accelerating innovation.

Investors should closely monitor Baird Medical's ability to translate its Chinese success to the U.S. market and its ongoing R&D efforts to maintain competitiveness in the rapidly evolving medical device industry.

NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China (which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clearances), and ExcelFin Acquisition Corp. ("ExcelFin") (NASDAQ: XFIN), a publicly traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination"). The listed company resulting from the Business Combination is Baird Medical Investment Holdings Limited ("PubCo"), and its shares and warrants will commence trading on the Nasdaq under the ticker symbols "BDMD" and "BDMDW", respectively, on October 2, 2024.

On September 26, 2024, ExcelFin held a special meeting of its stockholders (the "Special Meeting") to consider and vote upon a proposal to approve the Business Combination described in the proxy statement/prospectus. At the Special Meeting, in person or by proxy, the holders of 6,015,236 shares of ExcelFin's Class A common stock, constituting 91.36% of the issued and outstanding voting capital stock of ExcelFin entitled to vote, were present at the Special Meeting. Approximately 99.9% of the votes cast at the Special Meeting were in favor of approving the Business Combination. Complete official results of the vote are included in a current report on Form 8-K filed by ExcelFin with the U.S. Securities and Exchange Commission (the "SEC").

Upon completion of the Business Combination, founders of Baird Medical and Grand Fortune Capital, LLC, co-sponsor of ExcelFin Acquisition Corporation, subscribed to a $4,900,000 Convertible Preferred investment in the Company.

Advisors

Dechert LLP is serving as legal counsel to Baird Medical. Allen Overy Shearman Sterling US LLP is serving as legal counsel to ExcelFin. Cohen & Company Capital Markets, a division of J.V.B. Financial Group LLC, is serving as the lead financial advisor and capital markets advisor to ExcelFin, along with EXOS Capital LLC, Roth Capital LLC, and Haitong International Securities (USA) Inc.

Additional Information and Where to Find It

On June 26, 2023, ExcelFin, Baird Medical, PubCo, Betters Medical Merger Sub, Inc., Betters Medical Merger Sub 2, Inc., Betters Medical NewCo, LLC and Tycoon Choice Global Limited entered into a Business Combination Agreement as amended from time to time (the "Business Combination Agreement"). In connection with the transactions contemplated by the Business Combination Agreement (the "Transactions"), PubCo filed with the SEC a registration statement on Form F-4 (the "Registration Statement") (Registration No. 333-274114). The Registration Statement includes both the proxy statement that was distributed to ExcelFin's stockholders in connection with ExcelFin's solicitation of proxies for the vote by ExcelFin's stockholders with respect to the Business Combination and other matters as described in the Registration Statement, as well as the prospectus relating to the offer and sale of the securities of PubCo to be issued in connection with the Business Combination. The Registration Statement was declared effective by the SEC on September 5, 2024. Stockholders and investors may obtain free copies of the proxy statement/prospectus and other relevant materials and documents filed by PubCo and ExcelFin with the SEC at the SEC's website at www.sec.gov.

About Baird Medical

Established in 2012 and headquartered in Guangzhou, China, Baird Medical is a leading microwave ablation ("MWA") medical device manufacturer and provider in China (and a recent entrant to the United States market). Baird Medical's proprietary medical devices are used for the treatment of benign and malignant tumors including thyroid nodules, liver cancer, lung cancer and breast lumps. Baird Medical is the first company to obtain a Class III medical devices registration certificate for MWA medical devices specifically indicated for thyroid nodules in China. For more information, please visit http://www.bairdmed.com/.

About ExcelFin

ExcelFin is a blank check company formed as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. ExcelFin's sponsors include Grand Fortune Capital, LLC ("GFC") and Fin Venture Capital ("Fin"). GFC is an affiliate of an investment group that completed a series of significant M&A transactions and investments in FinTech, Technology, Media, and Telecommunications  and Healthcare. Fin is a private equity firm focused on FinTech software.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or ExcelFin's, Baird Medical's, PubCo's or Tycoon's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by ExcelFin and Baird Medical and their management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. None of PubCo, ExcelFin, or Baird Medical undertakes any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) risks related to the consummation of the Transactions; (2) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (3) the inability to recognize the anticipated benefits of the Transactions; (4) unexpected costs resulting from the Transactions; (5) changes in general economic conditions; (6) regulatory conditions and developments; (7) changes in applicable laws or regulations; (8) the nature, cost and outcome of pending and future litigation and other legal proceedings, including any such proceedings related to the Transactions and instituted against PubCo, ExcelFin, Baird Medical or others; and (9) other risks and uncertainties from time to time described in the Registration Statement relating to the Transactions, including those listed under the section titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by PubCo in connection with the Transactions. All subsequent written and oral forward-looking statements concerning ExcelFin, Baird Medical, PubCo or Tycoon, the Transactions described herein or other matters attributable to ExcelFin, Baird Medical, PubCo, Tycoon or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Each of ExcelFin, Baird Medical, PubCo and Tycoon expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contacts
Investor Relations
Robin Yang, Partner
ICR, LLC
Phone: +1 (646) 308-1475
Email: BairdMedical.IR@icrinc.com

Public Relations
Brad Burgess, Senior Vice President
ICR, LLC
Phone: +1 (646) 588-0383
Email: BairdMedical.PR@icrinc.com

Cision View original content:https://www.prnewswire.com/news-releases/baird-medical-and-excelfin-acquisition-corp-complete-business-combination-302264816.html

SOURCE ExcelFin Acquisition Corp

FAQ

When will Baird Medical Investment Holdings (BDMD) start trading on Nasdaq?

Baird Medical Investment Holdings (BDMD) will start trading on Nasdaq on October 2, 2024.

What was the voting result for the business combination between Baird Medical and ExcelFin (XFIN)?

Approximately 99.9% of the votes cast at ExcelFin's special meeting were in favor of approving the business combination.

What additional investment was made upon completion of the business combination?

Founders of Baird Medical and Grand Fortune Capital, subscribed to a $4,900,000 Convertible Preferred investment in the company upon completion of the business combination.

What will be the new ticker symbols for Baird Medical Investment Holdings after the merger with ExcelFin (XFIN)?

The new ticker symbols will be 'BDMD' for shares and 'BDMDW' for warrants on the Nasdaq stock exchange.

ExcelFin Acquisition Corp

NASDAQ:XFIN

XFIN Rankings

XFIN Latest News

XFIN Stock Data

60.84M
6.58M
87.33%
18.79%
Shell Companies
Blank Checks
Link
United States of America
SAN FRANCISCO